• Clinical science



Insulinomas are predominantly benign, pancreatic islet beta-cell tumors associated with increased insulin production. While most insulinomas are sporadic, some are associated with multiple endocrine neoplasias (e.g., parathyroid tumors, pituitary adenomas, gastrinomas). Insulinomas present clinically with recurrent attacks of hypoglycemic symptoms that subside after glucose intake. The diagnosis is established by demonstrating inappropriately elevated serum insulin following a fasting test. Insulinomas are differentiated from other causes of hyperinsulinemia (e.g., exogenous insulin administration) by the presence of elevated levels of proinsulin and C-peptide. The treatment of choice is surgical enucleation of the insulinoma. In inoperable cases and patients with persistent hypoglycemic attacks, diazoxide can be used to decrease insulin secretion.


  • Sex: >
  • Age range: ∼30–60 years
  • Incidence: ∼ 5 cases/1,000,000 persons per year


Epidemiological data refers to the US, unless otherwise specified.


  • Insulinomas are neuroendocrine tumors that arise from beta cells of the pancreas
    • ∼ 90% of insulinomas occur as solitary tumors
  • Most insulinomas occur sporadically
  • Over 90% of insulinomas are benign
  • ∼5% of insulinomas are associated with multiple endocrine neoplasia type 1 (MEN 1).


Clinical features

  • Clinical features of hypoglycemia
    • Relief of symptoms after administering glucose (See also Whipple's triad.)
  • Weight gain
  • Symptoms characteristic of other endocrine neoplasias may occur. (See MEN.)



Elevated C-peptide and proinsulin levels may also be the result of sulfonylurea use! This can be ruled out by screening serum samples for sulfonylureas.